NASHUA, N.H. – February 19, 2025 – iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”) a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today announced that five clinical presentations and abstracts highlighting the Company’s advancements in breast cancer detection, risk evaluation, and breast arterial calcification (BAC) assessment have been accepted for presentation at the European Congress of Radiology (ECR) 2025, which will take place from February 26 to March 2, 2025, in Vienna, Austria..

新罕布什尔州纳舒厄 – 2025年2月19日 – iCAD公司（纳斯达克股票代码：ICAD）（“iCAD”或“公司”），作为一家致力于通过提供经过临床验证的、由人工智能驱动的乳腺健康解决方案来创造一个癌症无处藏身的世界的全球领导者，今天宣布，在即将于2025年2月26日至3月2日在奥地利维也纳举行的2025年欧洲放射学大会（ECR）上，将有五项临床报告和摘要展示公司在乳腺癌检测、风险评估以及乳腺动脉钙化（BAC）评估方面的最新进展。

Led by research collaborators, these studies underscore iCAD’s commitment to delivering artificial intelligence (AI) powered solutions to advance personalized risk assessment, enhance early detection, and optimize breast imaging workflows.

这些研究由研究合作伙伴牵头，突显了iCAD致力于提供人工智能（AI）驱动的解决方案，以推进个性化风险评估、加强早期检测并优化乳腺成像工作流程。

“At iCAD, we are committed to pushing the boundaries of AI innovation in breast health, and the research being presented at ECR 2025 underscores the real-world impact and potential of our solutions,” said Dana Brown, President and CEO of iCAD. “These studies highlight how our solutions are advancing personalized risk evaluation, improving early detection, optimizing breast imaging workflows, and expanding the application of AI insights from a mammograph beyond breast health, ultimately supporting better outcomes for patients and providers worldwide.

“在iCAD，我们致力于推动乳腺健康领域的人工智能创新，而即将在ECR 2025上展示的研究突显了我们解决方案的实际影响和潜力，”iCAD总裁兼首席执行官达纳·布朗表示。“这些研究强调了我们的解决方案如何推进个性化风险评估、改善早期检测、优化乳腺成像工作流程，并将基于乳腺X光的AI洞察应用扩展到乳腺健康以外的领域，最终为全球患者和医疗服务提供者带来更好的结果。”

In line with this commitment, iCAD will present the new ProFound Cloud, a secure, scalable SaaS platform designed to deliver the company’s advanced AI solutions to healthcare providers worldwide”.

与此承诺一致，iCAD将推出新的ProFound Cloud，这是一个安全、可扩展的SaaS平台，旨在向全球医疗保健提供商提供该公司的先进AI解决方案。

Presentation Details:

演示详情：

Oral Presentations:

口头报告：

Title:

标题：

Optimal utilization of an AI diagnostic software in a mammography screening program in Switzerland

瑞士乳腺摄影筛查项目中AI诊断软件的最佳应用

Presenting Author:

报告作者：

Marcel Blum, St. Gallen, Switzerland

马塞尔·布卢姆，瑞士圣加仑

EPOS Virtual Abstract Presentation:

EPOS虚拟摘要展示：

iCAD will also showcase its latest AI-powered breast health innovations, including the ProFound Cloud which provides a fast, flexible and scalable access to iCAD’s ProFound full suite of solutions, including DBT Detection, 2D Detection, Density Assessment, and Risk. These presentations and live demonstrations at iCAD .

iCAD还将展示其最新的由人工智能驱动的乳腺健康创新产品，包括ProFound Cloud，它提供了快速、灵活且可扩展的访问方式，涵盖iCAD的ProFound全套解决方案，包括DBT检测、2D检测、密度评估和风险评估。这些展示和现场演示将在iCAD进行。

booth AI-27, Hall X-1

展位 AI-27，X-1厅

reinforce iCAD’s leadership in AI-driven breast health solutions, empowering radiologists with cutting-edge solutions to improve clinical outcomes, enhance workflow efficiency, and support personalized patient care.

加强iCAD在人工智能驱动的乳腺健康解决方案领域的领导地位，为放射科医生提供尖端解决方案，以改善临床结果、提高工作流程效率，并支持个性化患者护理。

For more information about iCAD’s participation at ECR 2025 or to schedule a demonstration, visit:

如需了解有关iCAD参加2025年ECR的更多信息或安排演示，请访问：

www.icadmed.com/about/news-events/upcoming-tradeshows-and-meetings/ecr-2025

www.icadmed.com/about/news-events/upcoming-tradeshows-and-meetings/ecr-2025

.

。

About iCAD, Inc.

关于iCAD公司

iCAD, Inc. (NASDAQ: ICAD) is a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes. Headquartered in Nashua, N.H., iCAD’s industry-leading ProFound Breast Health Suite provides AI-powered mammography analysis for breast cancer detection, density assessment and risk evaluation.

iCAD公司（纳斯达克股票代码：ICAD）是一家全球领先的公司，致力于通过提供经过临床验证的、由人工智能驱动的解决方案，创造一个癌症无处藏身的世界，使医疗服务提供者能够更早、更准确、更可靠地检测癌症，并改善患者的治疗效果。公司总部位于新罕布什尔州纳舒厄，其行业领先的ProFound乳腺健康套件利用人工智能进行乳腺癌检测、密度评估和风险评估的乳腺X光分析。

Used by thousands of providers serving millions of patients, ProFound is available in over 50 countries. In the last five years alone, iCAD estimates reading more than 40 million mammograms worldwide, with nearly 30% being tomosynthesis.  For more information, including the latest in regulatory clearances, please visit www.icadmed.com..

ProFound 已被数千家供应商使用，为数百万患者提供服务，现已在超过 50 个国家/地区推出。仅在过去五年中，iCAD 估计已在全球范围内读取了超过 4000 万份乳腺 X 光片，其中近 30% 为断层合成。如需更多信息，包括最新的监管批准，请访问 www.icadmed.com。

Forward-Looking Statements

前瞻性声明

Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the expansion of access to the Company’s products, improvement of performance, acceleration of adoption, expected benefits of ProFound AI®, the benefits of the Company’s products, and future prospects for the Company’s technology platforms and products.

本新闻稿中包含的某些陈述构成了1995年《私人证券诉讼改革法案》所指的“前瞻性陈述”，包括关于公司产品获取渠道的扩展、性能的提升、采用速度的加快、ProFound AI®的预期收益、公司产品的优势以及公司技术平台和产品的未来前景的陈述。

Such forward-looking statements involve a number of known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements.

此类前瞻性陈述涉及许多已知和未知的风险、不确定性及其他因素，这些因素可能导致公司的实际结果、业绩或成就与这些前瞻性陈述明示或暗示的任何未来结果、业绩或成就存在重大差异。

Such factors include, but are not limited, to the Company’s ability to achieve business and strategic objectives, the willingness of patients to undergo mammography screening, whether mammography screening will be treated as an essential procedure, whether ProFound AI will improve reading efficiency, improve specificity and sensitivity, reduce false positives and otherwise prove to be more beneficial for patients and clinicians, the impact of supply and manufacturing constraints or difficulties on our ability to fulfill our orders, uncertainty of future sales levels, to defend itself in litigation matters, protection of patents and other proprietary rights, product market acceptance, possible technological obsolescence of products, increased competition, government regulation, changes in Medicare orother reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the.

此类因素包括但不限于公司实现业务和战略目标的能力、患者接受乳腺X光筛查的意愿、乳腺X光筛查是否会被视为必要程序、ProFound AI是否能够提高读片效率、提高特异性和敏感性、减少假阳性并总体上证明对患者和临床医生更有益、供应和制造限制或困难对我们履行订单能力的影响、未来销售水平的不确定性、在诉讼事项中自我辩护的能力、专利和其他专有权利的保护、产品市场接受度、产品可能的技术过时、竞争加剧、政府监管、医疗保险或其他报销政策的变化、与我们现有及未来债务义务相关的风险、竞争因素、公司所服务经济或市场下滑的影响；以及其他详细说明中的风险。

CONTACTS

联系人

Media inquiries:

媒体询问：

pr@icadmed.com

pr@icadmed.com

Investor Inquiries:

投资者查询：

John Nesbett/Rosalyn Christian

约翰·内斯贝特/罗莎琳·克里斯蒂安

IMS Investor Relations

IMS投资者关系

icad@imsinvestorrelations.com

icad@imsinvestorrelations.com